Versant Capital Management’s Castle Biosciences CSTL Stock Holding History

Versant Capital Management’s Portfolio CSTL Stock Details CSTL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$5.47K	Buy	154 +28	+22%	+$845	﹤0.01%	2439
2026 Q2	$3K	Sell	126 -120	-49%	-$2.67K	﹤0.01%	2512
2026 Q1	$6.04K	Buy	246 +65	+36%	+$2.13K	﹤0.01%	2329
2025 Q4	$7.04K	Hold	181	–	–	﹤0.01%	2124
2025 Q3	$4.12K	Buy	181 +55	+44%	+$1.12K	﹤0.01%	2279
2025 Q2	$2.57K	Buy	+126	New	+$2.33K	﹤0.01%	2336

Other funds holding CSTL

Wasatch Advisors Salt Lake City, Utah $13.5B AUM 16.58% 1-Year Est. Return

KBC Group Brussels, Belgium $47.9B AUM 37.61% 1-Year Est. Return

Harbor Capital Advisors Chicago, Illinois $1.48B AUM 30.88% 1-Year Est. Return

FBT

First Bank & Trust Brookings, South Dakota $687M AUM 18.35% 1-Year Est. Return

Inspire Investing Meridian, Idaho $2.37B AUM 29.82% 1-Year Est. Return

Diversify Advisory Services Sandy, Utah $6.69B AUM 18.85% 1-Year Est. Return

Diversify Wealth Management Sandy, Utah $6.69B AUM 22.4% 1-Year Est. Return

Green Alpha Advisors Niwot, Colorado $148M AUM 98.22% 1-Year Est. Return

Oak Harvest Investment Services Houston, Texas $1.07B AUM 32.83% 1-Year Est. Return

Wealth Enhancement Advisory Services Plymouth, Minnesota $67.3B AUM 21.9% 1-Year Est. Return

Versant Capital Management's CSTL Position: Q3 2026 in Review

Versant Capital Management increased its Castle Biosciences (CSTL) stake by 22% in Q3 2026, buying an estimated $845 and bringing the position to 154 shares worth $5.47K. The position accounts for ﹤0.01% of the portfolio, ranked #2439.

Versant Capital Management first reported a position in CSTL in Q2 2025 and has held it in 6 quarters since. The position peaked at $7.04K in Q4 2025. 24 funds tracked by Wall St. Rank hold CSTL as of Q3 2026.

Versant Capital Management held 154 shares of Castle Biosciences worth $5.47K as of Q3 2026.
Versant Capital Management bought 28 Castle Biosciences shares in Q3 2026, an estimated $845.
Castle Biosciences made up ﹤0.01% of Versant Capital Management's portfolio in Q3 2026, its #2439 holding.
Versant Capital Management first reported a position in Castle Biosciences in Q2 2025 and has held it in 6 quarters since.
Versant Capital Management's Castle Biosciences position peaked at $7.04K in Q4 2025.
24 funds tracked by Wall St. Rank held Castle Biosciences as of Q3 2026.

Based on Versant Capital Management's 13F filing for Q3 2026, filed 2 Oct 2026.